Ewing sarcoma

[1]  U. Dirksen,et al.  Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma , 2018, Pediatric blood & cancer.

[2]  A. Llombart‐Bosch,et al.  Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis. , 2018, Annals of diagnostic pathology.

[3]  O. Delattre,et al.  Transcriptomic definition of molecular subgroups of small round cell sarcomas , 2018, The Journal of pathology.

[4]  R. Norris,et al.  Phase 1 trial of ontuxizumab (MORAb‐004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213) , 2018, Pediatric blood & cancer.

[5]  K. Paigen,et al.  PRDM9 and Its Role in Genetic Recombination. , 2018, Trends in genetics : TIG.

[6]  K. Stegmaier,et al.  EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma , 2018, Nature.

[7]  K. Scotlandi,et al.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors , 2018, Genes.

[8]  U. Dirksen,et al.  Recurrence of Ewing sarcoma: Is detection by imaging follow‐up protocol associated with survival advantage? , 2018, Pediatric blood & cancer.

[9]  A. Llombart‐Bosch,et al.  Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT) , 2018, Virchows Archiv.

[10]  U. Dirksen,et al.  Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Nilay Shah,et al.  HOTAIR primes the Ewing sarcoma family of tumors for tumorigenesis via epigenetic dysregulation involving LSD1 , 2018, bioRxiv.

[12]  K. Scotlandi,et al.  CD99 at the crossroads of physiology and pathology , 2018, Journal of Cell Communication and Signaling.

[13]  U. Dirksen,et al.  Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas , 2018, Pediatric blood & cancer.

[14]  J. Blay,et al.  A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome , 2017, Scientific Reports.

[15]  T. Kwee,et al.  Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? , 2017, Skeletal Radiology.

[16]  U. Dirksen,et al.  Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma , 2017, Science Signaling.

[17]  C. Antonescu,et al.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas , 2017, The American journal of surgical pathology.

[18]  M. Rivera,et al.  Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain , 2017, Cell.

[19]  T. Kirchner,et al.  Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas? , 2017, Cancer research.

[20]  F. Tirode,et al.  Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas. , 2017, Surgical pathology clinics.

[21]  S. Lessnick,et al.  Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth , 2017, Proceedings of the National Academy of Sciences.

[22]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[23]  P. Varlet,et al.  Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.

[24]  M. Kauer,et al.  EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma , 2017, Oncogene.

[25]  U. Dirksen,et al.  Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets , 2017, bioRxiv.

[26]  G. Armstrong,et al.  Longitudinal follow‐up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study , 2017, Cancer.

[27]  C. Antonescu,et al.  Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases , 2017, The American journal of surgical pathology.

[28]  Catarina P. Santos,et al.  Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts , 2017, bioRxiv.

[29]  C. R. Galia,et al.  What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group – EWING1 , 2017, BMC Cancer.

[30]  Chunsheng Han,et al.  Gene knockout of Zmym3 in mice arrests spermatogenesis at meiotic metaphase with defects in spindle assembly checkpoint , 2017, Cell Death and Disease.

[31]  P. Sorensen,et al.  Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells , 2017, Oncoimmunology.

[32]  D. Rosenbaum,et al.  Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Surdez,et al.  EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma , 2017, Oncogene.

[34]  P. Jedlicka,et al.  The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis , 2017, Oncogene.

[35]  D. Durocher,et al.  ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair , 2017, Genes & development.

[36]  U. Dirksen,et al.  Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells , 2017, Oncogene.

[37]  Nathan C. Sheffield,et al.  DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma , 2017, Nature Medicine.

[38]  J. Khan,et al.  Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma Germline mutations in Ewing sarcoma , 2016, Genetics in Medicine.

[39]  J. Simon,et al.  Widespread Chromatin Accessibility at Repetitive Elements Links Stem Cells with Human Cancer. , 2016, Cell reports.

[40]  M. Martinelli,et al.  CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression , 2016, Oncotarget.

[41]  A. D. Dei Tos,et al.  CIC–DUX4 fusion‐positive round‐cell sarcomas of soft tissue and bone: a single‐institution morphological and molecular analysis of seven cases , 2016, Histopathology.

[42]  C. Hartmann,et al.  Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation , 2016, Cell Death and Disease.

[43]  Dafydd G. Thomas,et al.  Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. , 2016, Cancer research.

[44]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[45]  M. Krook,et al.  Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma , 2016, Neoplasia.

[46]  D. Herrero-Martín,et al.  Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway , 2016, Oncotarget.

[47]  U. Dirksen,et al.  Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. , 2016, European journal of cancer.

[48]  M. Ayers,et al.  A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma , 2016, Pediatric blood & cancer.

[49]  U. Dirksen,et al.  Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.

[50]  Yan Guo,et al.  BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma , 2016, Oncotarget.

[51]  G. Vunjak‐Novakovic,et al.  Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model , 2016, Theranostics.

[52]  U. Dirksen,et al.  Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). , 2016 .

[53]  U. Dirksen,et al.  Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial. , 2016 .

[54]  U. Dirksen,et al.  Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc). , 2016 .

[55]  D. Surdez,et al.  Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model , 2016, Oncotarget.

[56]  U. Dirksen,et al.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease , 2016, Molecular oncology.

[57]  S. Dry,et al.  Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS‐ERG and common pitfalls in detecting EWSR1‐ERG fusions by FISH , 2016, Genes, chromosomes & cancer.

[58]  J. Khan,et al.  MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research , 2016, Clinical Cancer Research.

[59]  S. Lessnick,et al.  Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting , 2016, Oncotarget.

[60]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[61]  S. Steinberg,et al.  Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas , 2016, Clinical Cancer Research.

[62]  Nathan C. Sheffield,et al.  The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease , 2016, Oncotarget.

[63]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[64]  L. Di Croce,et al.  Regulation of gene transcription by Polycomb proteins , 2015, Science Advances.

[65]  B. Schäfer,et al.  Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma , 2015, Oncotarget.

[66]  H. Schreuder,et al.  The Neurological Compromised Spine Due to Ewing Sarcoma. What First: Surgery or Chemotherapy? Therapy, Survival, and Neurological Outcome of 15 Cases With Primary Ewing Sarcoma of the Vertebral Column. , 2015, Neurosurgery.

[67]  F. Engert,et al.  PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway , 2015, Molecular Cancer Therapeutics.

[68]  C. Rodríguez-Galindo,et al.  Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian Collaborative Study Group for Ewing Sarcoma Family Tumors—EWING1 , 2015, Pediatric blood & cancer.

[69]  P. Houghton,et al.  Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation , 2015, Front. Oncol..

[70]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Bhan,et al.  LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. , 2015, Biochimica et biophysica acta.

[72]  T. Gorr,et al.  IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells , 2015, BMC Cancer.

[73]  S. Chanock,et al.  Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite , 2015, Nature Genetics.

[74]  J. Alonso,et al.  EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma , 2015, Front. Oncol..

[75]  P. Sorensen,et al.  Stress-mediated translational control in cancer cells. , 2015, Biochimica et biophysica acta.

[76]  U. Dirksen,et al.  Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial , 2015, Annals of Surgical Oncology.

[77]  G. Crabtree,et al.  Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics , 2015, Science Advances.

[78]  J. Mora,et al.  Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2017, OncoTarget.

[79]  P. Sorensen,et al.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.

[80]  P. Sorensen,et al.  YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1 , 2015, The Journal of cell biology.

[81]  N. Senzer,et al.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  Nathan C. Sheffield,et al.  Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1 , 2015, Cell reports.

[83]  S. Donaldson,et al.  Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group , 2015, Cancer.

[84]  Jason U Tilan,et al.  High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases , 2015, Oncotarget.

[85]  T. Triche,et al.  Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour–stromal interactions: a report from the Children's Oncology Group , 2015, The journal of pathology. Clinical research.

[86]  Chengcheng Hu,et al.  Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma , 2015, Pediatric blood & cancer.

[87]  E. Alba,et al.  Time to diagnosis of ewing tumors in children and adolescents is not associated with metastasis or survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Marcus R. Breese,et al.  Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. , 2014, The Journal of clinical investigation.

[89]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[90]  A. Llombart‐Bosch,et al.  Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. , 2014, Cancer research.

[91]  Shawn M. Gillespie,et al.  EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. , 2014, Cancer cell.

[92]  Abbas Shirinifard,et al.  Targeting the DNA repair pathway in Ewing sarcoma. , 2014, Cell reports.

[93]  M. Beckerle,et al.  Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma , 2014, Molecular biology of the cell.

[94]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[95]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[96]  U. Dirksen,et al.  Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  U. Dirksen,et al.  The value of high‐dose chemotherapy in patients with first relapsed Ewing sarcoma , 2014, Pediatric blood & cancer.

[98]  X J Li,et al.  MicroRNA-34a: a potential therapeutic target in human cancer , 2014, Cell Death and Disease.

[99]  K. Igarashi,et al.  Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. , 2014, The Journal of clinical investigation.

[100]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[101]  M. Beckerle,et al.  Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth , 2014, Clinical Cancer Research.

[102]  L. Doyle,et al.  Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone , 2014, Cancer.

[103]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[104]  KyungMann Kim,et al.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  R. Norris,et al.  Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study , 2014, Pediatric blood & cancer.

[106]  L. Helman,et al.  New Strategies in Ewing Sarcoma: Lost in Translation? , 2014, Clinical Cancer Research.

[107]  Dafydd G. Thomas,et al.  Stress-Induced CXCR4 Promotes Migration and Invasion of Ewing Sarcoma , 2014, Molecular Cancer Research.

[108]  R. Gorlick,et al.  Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma , 2014, Cancer.

[109]  E. Kleinerman,et al.  EWS‐FLI‐1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology , 2014, Cancer.

[110]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[111]  J. Hornick.  Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors , 2014, Modern Pathology.

[112]  C. Wahlestedt,et al.  Non-coding RNAs as direct and indirect modulators of epigenetic regulation , 2014, Epigenetics.

[113]  U. Dirksen,et al.  The Zyxin‐related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth , 2013, Biology of the cell.

[114]  Elizabeth T. Wiles,et al.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. , 2013, Genes & cancer.

[115]  Y. Akao,et al.  Ewing Sarcoma Cells Secrete EWS/Fli-1 Fusion mRNA via Microvesicles , 2013, PloS one.

[116]  C. Rodríguez-Galindo,et al.  Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma , 2013, Pediatric blood & cancer.

[117]  P. Meltzer,et al.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer , 2013, Genome research.

[118]  G. Raposo,et al.  First identification of Ewing's sarcoma‐derived extracellular vesicles and exploration of their biological and potential diagnostic implications , 2013, Biology of the cell.

[119]  Robin L. Jones,et al.  An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma , 2013, Pediatric blood & cancer.

[120]  A. Nicholson,et al.  ERBB4 confers metastatic capacity in Ewing sarcoma , 2013, EMBO molecular medicine.

[121]  S. Fulda,et al.  G‐Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1 , 2013, The Journal of pathology.

[122]  Layne Dylla,et al.  MicroRNAs in Ewing Sarcoma , 2013, Front. Oncol..

[123]  U. Dirksen,et al.  Genomic EWS-FLI1 Fusion Sequences in Ewing Sarcoma Resemble Breakpoint Characteristics of Immature Lymphoid Malignancies , 2013, PloS one.

[124]  S. Burdach,et al.  DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. , 2013, Cancer research.

[125]  R. Bell,et al.  Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma , 2012, Oncogene.

[126]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  M. Eriksson,et al.  Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[128]  S. Ferrari,et al.  Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients , 2012, Cancer.

[129]  S. Lessnick,et al.  EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors , 2012, Clinical Cancer Research.

[130]  Nicolò Riggi,et al.  A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. , 2012, Cancer cell.

[131]  L. Jorde,et al.  EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. , 2012, Cancer genetics.

[132]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[133]  M. Ferracin,et al.  miR‐34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo‐sensitivity and malignancy , 2012, The Journal of pathology.

[134]  E. Álava,et al.  1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma , 2012, Oncogene.

[135]  O. Delattre,et al.  A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion , 2012, Nature Genetics.

[136]  D. Rao,et al.  Phase I Trial of "bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[137]  U. Dirksen,et al.  The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting , 2012, British Journal of Cancer.

[138]  F. Clavel-Chapelon,et al.  Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma , 2012, Nature Genetics.

[139]  J. Lieb,et al.  Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. , 2012, Genome research.

[140]  U. Dirksen,et al.  Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  A. Sickmann,et al.  STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors , 2011, Molecular Cancer Research.

[142]  D. Rakheja,et al.  A zebrafish transgenic model of Ewing’s sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis , 2011, Disease Models & Mechanisms.

[143]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[144]  Y. Iwamoto,et al.  Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. , 2011, The American journal of pathology.

[145]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[146]  P. Wade,et al.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex , 2011, Nature Reviews Cancer.

[147]  U. Dirksen,et al.  No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[148]  S. Lessnick,et al.  Promiscuous partnerships in Ewing's sarcoma. , 2011, Cancer genetics.

[149]  D. Strunk,et al.  Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma , 2011, Oncogene.

[150]  S. Ferrari,et al.  Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[151]  E. Kleinerman,et al.  Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing’s sarcoma in the lung , 2011, Angiogenesis.

[152]  Aaron R Cooper,et al.  Modeling Initiation of Ewing Sarcoma in Human Neural Crest Cells , 2011, PloS one.

[153]  G. Felsenfeld,et al.  Specific Sites in the C Terminus of CTCF Interact with the SA2 Subunit of the Cohesin Complex and Are Required for Cohesin-Dependent Insulation Activity , 2011, Molecular and Cellular Biology.

[154]  M. Schilham,et al.  Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression , 2011, The Journal of pathology.

[155]  J. Neuhaus,et al.  Racial Differences in the Incidence of Mesenchymal Tumors Associated with EWSR1 Translocation , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[156]  O. Delattre,et al.  Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.

[157]  K. Ness,et al.  Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. , 2010, Journal of the National Cancer Institute.

[158]  J. Schiffman,et al.  Recent advances in the molecular pathogenesis of Ewing's sarcoma , 2010, Oncogene.

[159]  W. Kraus,et al.  SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. , 2010, Biochimica et biophysica acta.

[160]  U. Dirksen,et al.  Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  Y. Okada,et al.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway , 2010, British Journal of Cancer.

[162]  A. Wood,et al.  Condensin and cohesin complexity: the expanding repertoire of functions , 2010, Nature Reviews Genetics.

[163]  P. Meltzer,et al.  Molecular and Cellular Pathobiology Cancer Research Hypoxia Modulates EWS-FLI 1 Transcriptional Signature and Enhances the Malignant Properties of Ewing ' s Sarcoma Cells In vitro , 2010 .

[164]  Nicolò Riggi,et al.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. , 2010, Genes & development.

[165]  U. Dirksen,et al.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  T. Triche,et al.  Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  Annalisa Astolfi,et al.  CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. , 2010, The Journal of clinical investigation.

[168]  C. Hill,et al.  Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma. , 2010, Genes & cancer.

[169]  U. Dirksen,et al.  The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) , 2010, Cancer.

[170]  K. Matthay,et al.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow , 2010, Pediatric blood & cancer.

[171]  A. Llombart‐Bosch,et al.  Molecular Diagnosis of Ewing Sarcoma Family of Tumors: A Comparative Analysis of 560 Cases With FISH and RT-PCR , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[172]  E. Kleinerman,et al.  Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. , 2009, In vivo.

[173]  A. Llombart‐Bosch,et al.  Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support , 2009, Virchows Archiv.

[174]  L. Koniaris,et al.  Ewing sarcoma demonstrates racial disparities in incidence‐related and sex‐related differences in outcome , 2009, Cancer.

[175]  U. Dirksen,et al.  Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition , 2009, The Journal of pathology.

[176]  A. Üren,et al.  Small molecule selected to disrupt oncogenic protein EWS-FLI1 interaction with RNA Helicase A inhibits Ewing's Sarcoma , 2009, Nature Medicine.

[177]  G. Pan,et al.  MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells , 2009, Cell.

[178]  H. Tanke,et al.  The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology , 2009, Clinical Cancer Research.

[179]  E. Barillot,et al.  The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function , 2009, PloS one.

[180]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[181]  M. Bernstein,et al.  Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells , 2008, Cancer Cell International.

[182]  W. Shi,et al.  Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. , 2008, International journal of radiation oncology, biology, physics.

[183]  P. Lin,et al.  EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. , 2008, Cancer Research.

[184]  M. Kauer,et al.  EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. , 2008, Cancer research.

[185]  Aaron R Cooper,et al.  BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. , 2008, Cancer research.

[186]  Stephen C. Haroldsen,et al.  Microsatellites as EWS/FLI response elements in Ewing's sarcoma , 2008, Proceedings of the National Academy of Sciences.

[187]  M. Suvà,et al.  EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. , 2008, Cancer research.

[188]  S. Burchill,et al.  Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: A study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group , 2008, Genes, chromosomes & cancer.

[189]  S. Lessnick,et al.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature , 2008, Cell cycle.

[190]  L. Mahadevan,et al.  Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation , 2007, The EMBO journal.

[191]  H. Gerth,et al.  Significant Benefit of Multimodal Imaging: PET/CT Compared with PET Alone in Staging and Follow-up of Patients with Ewing Tumors , 2007, Journal of Nuclear Medicine.

[192]  Thomas Völker,et al.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  P. Sorensen,et al.  Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. , 2007, The Journal of molecular diagnostics : JMD.

[194]  I. Wood,et al.  Chromatin crosstalk in development and disease: lessons from REST , 2007, Nature Reviews Genetics.

[195]  S. Burchill,et al.  Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT , 2007, British Journal of Cancer.

[196]  A. Spurdle,et al.  A Novel Corepressor, BCoR-L1, Represses Transcription through an Interaction with CtBP* , 2007, Journal of Biological Chemistry.

[197]  U. Völker,et al.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells , 2007, Journal of Cancer Research and Clinical Oncology.

[198]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[199]  P. Terrier,et al.  Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  A. Craft,et al.  Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial , 2006, Pediatric blood & cancer.

[201]  Paul Tempst,et al.  JHDM2A, a JmjC-Containing H3K9 Demethylase, Facilitates Transcription Activation by Androgen Receptor , 2006, Cell.

[202]  R. Kofler,et al.  Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells , 2006, Oncogene.

[203]  A. Trumpp,et al.  Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. , 2005, Cancer research.

[204]  J. Goldblum,et al.  Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiation , 2005, Modern Pathology.

[205]  J. Richardson,et al.  Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. , 2005, Cancer research.

[206]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  S. Burdach,et al.  DNA Microarrays Reveal Relationship of Ewing Family Tumors to Both Endothelial and Fetal Neural Crest-Derived Cells and Define Novel Targets , 2004, Cancer Research.

[208]  P. Picci,et al.  Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[209]  N. Tarbell,et al.  Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest Wall: Impact of Initial Versus Delayed Resection on Tumor Margins, Survival, and Use of Radiation Therapy , 2003, Annals of surgery.

[210]  J. Haerting,et al.  High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  M. Ladanyi,et al.  Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells , 2003, Oncogene.

[212]  S. Knuutila,et al.  Prognostic impact of chromosomal aberrations in Ewing tumours , 2002, British Journal of Cancer.

[213]  T. Merchant,et al.  Fractures in Pediatric Ewing Sarcoma , 2001, Journal of pediatric hematology/oncology.

[214]  H. Hense,et al.  Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[215]  M. Ladanyi,et al.  High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  S. Ferrari,et al.  Ewing's sarcoma of bone: relation between clinical characteristics and staging. , 2001, Oncology reports.

[217]  O. Schober,et al.  FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[218]  O. Larsson,et al.  A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells , 2000, Oncogene.

[219]  E. Verdin,et al.  BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.

[220]  B. Widhe,et al.  Initial Symptoms and Clinical Features in Osteosarcoma and Ewing Sarcoma* , 2000, The Journal of bone and joint surgery. American volume.

[221]  P. Sorensen,et al.  Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein , 1999, Nature Genetics.

[222]  P. Sorensen,et al.  EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  W. Winkelmann,et al.  Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  J. Hata,et al.  Molecular Analysis of Ewing's Sarcoma: Another Fusion Gene, EWS‐E1AF, Available for Diagnosis , 1998, Japanese journal of cancer research : Gann.

[225]  H. Kovar,et al.  Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. , 1998, Current opinion in oncology.

[226]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  D. Leroith,et al.  The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* , 1997, The Journal of Biological Chemistry.

[228]  G. Thomas,et al.  A new member of the ETS family fused to EWS in Ewing tumors , 1997, Oncogene.

[229]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[230]  S. Burdach,et al.  Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. , 1995, Bone marrow transplantation.

[231]  C. Denny,et al.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. , 1995, Oncogene.

[232]  C. Denny,et al.  Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. , 1995, Oncogene.

[233]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[234]  E. Reddy,et al.  EWS/Fli-1 chimeric protein is a transcriptional activator. , 1993, Cancer research.

[235]  T. Triche,et al.  Combinatorial generation of variable fusion proteins in the Ewing family of tumours. , 1993, The EMBO journal.

[236]  P. Sorensen,et al.  Reverse Transcriptase PCR Amplification of EWS/FLI‐1 Fusion Transcripts as a Diagnostic Test for Peripheral Primitive Neuroectodermal Tumors of Childhood , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[237]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[238]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[239]  H Kovar,et al.  MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration , 1991, Cancer.

[240]  A. Aurias,et al.  Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). , 1988, Cancer genetics and cytogenetics.

[241]  U. Göbel,et al.  Die GPO cooperativen Ewing-Sarkom Studien CESS 81/86: , 1988 .

[242]  A. Aurias,et al.  Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. , 1984, Cancer genetics and cytogenetics.

[243]  A. Schiller,et al.  Ewing's sarcoma in female siblings: A clinical report and review of the literature , 1984, Cancer.

[244]  K. Cooper,et al.  A clinicopathologic study of 20 cases of large‐cell (atypical) Ewing's sarcoma of bone , 1980, The American journal of surgical pathology.

[245]  J. Ewing.  Diffuse endothelioma of bone , 1972 .

[246]  R. Drake,et al.  Rarity of Ewing's tumour in Negroes. , 1970, Lancet.

[247]  J. Fraumeni,et al.  Rarity of Ewing's sarcoma among U.S. Negro children. , 1970, Lancet.

[248]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[249]  D. Rao,et al.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[250]  E. Kluczewska,et al.  Suitability of imaging methods (X-ray, CT, MRI) in the diagnostics of Ewing’s sarcoma in children – analysis of own material , 2010, Polish journal of radiology.

[251]  C. Beauchamp.  Ewing Sarcoma Demonstrates Racial Disparities in Incidence-related and Sex-related Differences in Outcome: An Analysis of 1631 Cases From the SEER Database, 1973-2005 , 2010 .

[252]  A. Üren,et al.  A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma , 2009 .

[253]  Gail M. Williams,et al.  Farm exposures, parental occupation, and risk of Ewing's sarcoma in Australia: a national case–control study , 2004, Cancer Causes & Control.

[254]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[255]  W. Winkelmann,et al.  Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. , 2003, International journal of radiation oncology, biology, physics.

[256]  K. Hahm.  Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein , 1999, Nature Genetics.

[257]  S. Ferrari,et al.  Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. , 1998, Acta oncologica.

[258]  J. Dunst,et al.  [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 1/2 years]. , 1988, Klinische Padiatrie.